OTLK Launches LYTENAVA in Europe, Faces US FDA Hurdles for Wet AMD Drug

TL;DR

**OTLK is a high-risk bet, with European launch revenue offset by persistent US FDA rejection and a 'going concern' warning that screams cash crunch.**

AI Summary

Outlook Therapeutics, Inc. (OTLK) reported significant developments for its ophthalmic formulation of bevacizumab, ONS-5010/LYTENAVA, for wet age-related macular degeneration (wet AMD). The company successfully launched the product in Germany and the UK in June 2025, following marketing authorization from the European Commission in May 2024 and the MHRA in July 2024. Despite these international successes, OTLK faces ongoing challenges in the United States, having received a second Complete Response Letter (CRL) from the FDA in August 2025 for its BLA, citing a lack of substantial evidence of effectiveness and requiring additional well-controlled clinical evidence. The company resubmitted the BLA with a PDUFA goal date of December 31, 2025. OTLK estimates the global anti-VEGF retina market to be approximately $16 billion, with significant opportunities in Europe ($3.6 billion) and the United States ($8.5 billion), where off-label bevacizumab use is prevalent. The company continues to incur significant losses and negative cash flows, with substantial doubt about its ability to continue as a going concern, necessitating additional funding.

Why It Matters

Outlook Therapeutics' ability to commercialize ONS-5010/LYTENAVA in the EU and UK provides a crucial revenue stream, but the repeated FDA setbacks in the US are a major concern for investors. The US market, estimated at $8.5 billion for anti-VEGF retina treatments, represents a significant opportunity that OTLK is struggling to access, leaving a void for competitors. Employees face uncertainty given the 'going concern' warning, while patients in the EU and UK gain access to the first approved ophthalmic bevacizumab, potentially mitigating risks associated with off-label use. The competitive landscape remains intense, with other approved anti-VEGF therapies already established.

Risk Assessment

Risk Level: high — The company explicitly states, 'We have incurred significant losses and negative cash flows from operations since our inception and expect to continue to incur significant losses and negative cash flows from operations for at least the next 12 months.' Furthermore, there is 'substantial doubt about our ability to continue as a going concern,' directly indicating severe financial instability and a high probability of needing substantial additional funding.

Analyst Insight

Investors should exercise extreme caution and consider the significant financial and regulatory risks before investing in OTLK. Monitor the FDA's December 31, 2025 PDUFA decision closely, as a positive outcome could provide a short-term catalyst, but the long-term viability hinges on securing substantial additional funding and achieving profitability.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $26.9 million — aggregate market value of common stock held by non-affiliates (as of March 31, 2025, indicating a relatively small market capitalization)
• 64,114,399 — shares of common stock outstanding (as of December 16, 2025)
• $3.6 billion — estimated total anti-VEGF retina market in Europe (represents a significant market opportunity for ONS-5010/LYTENAVA)
• $8.5 billion — estimated total anti-VEGF retina market in the United States (represents a critical, yet currently inaccessible, market for ONS-5010/LYTENAVA)
• $16 billion — estimated global market for anti-VEGF retina (overall market size for ONS-5010/LYTENAVA)
• 2.8 million — annual off-label bevacizumab injections in Europe (highlights the existing demand ONS-5010/LYTENAVA aims to capture)
• 2.7 million — annual off-label bevacizumab injections in the United States (underscores the potential US market if approved)
• 55% — of US physicians prefer off-label repackaged bevacizumab as first-line product (indicates strong market preference ONS-5010/LYTENAVA could address with approval)
• 34% — of total US anti-VEGF market is off-label bevacizumab (demonstrates the significant segment ONS-5010/LYTENAVA could penetrate)

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — registrant
• ONS-5010/LYTENAVA (company) — primary product candidate
• European Commission (regulator) — granted Marketing Authorization in May 2024
• MHRA (regulator) — granted marketing authorization in July 2024
• FDA (regulator) — issued second Complete Response Letter in August 2025
• GMS Ventures and Investments (company) — significant common stock owner
• Germany (company) — initial launch market for ONS-5010/LYTENAVA
• United Kingdom (company) — initial launch market for ONS-5010/LYTENAVA
• Nasdaq Stock Market LLC (company) — exchange where common stock is registered

FAQ

Risk Factors

• FDA Approval Uncertainty for ONS-5010/LYTENAVA in the US [high — regulatory]: Outlook Therapeutics received a second Complete Response Letter (CRL) from the FDA in August 2025 for its BLA, citing a lack of substantial evidence of effectiveness. The company has resubmitted the BLA with a PDUFA goal date of December 31, 2025. Failure to obtain FDA approval would significantly hinder the company's ability to access the critical US market, estimated at $8.5 billion.
• Substantial Doubt About Going Concern [high — financial]: The company continues to incur significant losses and negative cash flows. This financial situation raises substantial doubt about its ability to continue as a going concern, indicating a high dependence on future funding to sustain operations and pursue its commercialization efforts.
• Competition in the Anti-VEGF Retina Market [medium — market]: The global anti-VEGF retina market is estimated at $16 billion, with significant competition. While ONS-5010/LYTENAVA aims to capture market share from off-label bevacizumab use (2.7 million injections annually in the US, 2.8 million in Europe), other approved anti-VEGF therapies exist and may pose competitive challenges.
• Dependence on Key Product Success [medium — operational]: The company's future is heavily reliant on the successful commercialization of ONS-5010/LYTENAVA. Any setbacks in manufacturing, distribution, or market adoption in Europe or future markets could severely impact financial performance.
• International Regulatory Compliance and Market Access [medium — regulatory]: While ONS-5010/LYTENAVA has received marketing authorization in the EU and UK, ongoing compliance with evolving international regulations and successful market penetration in these regions are critical. Differences in regulatory requirements across various markets could also present challenges.

Industry Context

The anti-VEGF retina market is a substantial and growing sector, driven by the increasing prevalence of age-related macular degeneration and diabetic retinopathy. While several approved therapies exist, a significant portion of the market, particularly in the US and Europe, is served by off-label use of bevacizumab due to its efficacy and lower cost. Companies like Outlook Therapeutics are seeking to capture this segment with approved, ophthalmic formulations of bevacizumab, aiming to offer a more standardized and potentially safer alternative to repackaged drugs.

Regulatory Implications

Outlook Therapeutics faces significant regulatory hurdles, particularly with the FDA's repeated Complete Response Letters for ONS-5010/LYTENAVA. The need for additional clinical evidence highlights the stringent requirements for demonstrating effectiveness in the US market. While European approvals have been secured, ongoing compliance and potential future regulatory changes in other markets remain critical considerations.

What Investors Should Do

1. Monitor FDA's decision on the resubmitted BLA for ONS-5010/LYTENAVA by the December 31, 2025 PDUFA date.
2. Evaluate the commercial performance of ONS-5010/LYTENAVA in Germany and the UK.
3. Assess the company's ability to secure additional funding.
4. Track competitive developments in the anti-VEGF retina market.

Key Dates

• 2024-05-01: European Commission Marketing Authorization for ONS-5010/LYTENAVA — First major regulatory approval for the company's lead product, enabling market entry in the EU.
• 2024-07-01: MHRA Marketing Authorization for ONS-5010/LYTENAVA — Secured regulatory approval in the UK, complementing the EU authorization and expanding European market access.
• 2025-06-01: Launch of ONS-5010/LYTENAVA in Germany and the UK — Commercialization of the company's lead product in key European markets, marking a significant milestone.
• 2025-08-01: Second Complete Response Letter (CRL) from FDA for ONS-5010/LYTENAVA BLA — Major setback for US market entry, requiring additional clinical evidence and delaying potential approval.
• 2025-12-31: PDUFA Goal Date for ONS-5010/LYTENAVA BLA Resubmission — Critical date for potential FDA approval in the US, which is essential for accessing a major market.

Glossary

Bevacizumab

A full-length, humanized monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF), used to treat certain cancers and, in ophthalmic formulations, retinal diseases. (The active pharmaceutical ingredient in ONS-5010/LYTENAVA, central to the company's product and market strategy.)

VEGF (Vascular Endothelial Growth Factor)

A signaling protein that stimulates the growth of blood vessels, implicated in diseases like wet age-related macular degeneration (wet AMD). (The target of bevacizumab, explaining the therapeutic mechanism of ONS-5010/LYTENAVA.)

Wet Age-Related Macular Degeneration (wet AMD)

A progressive eye disease characterized by abnormal blood vessel growth in the macula, leading to vision loss. (The primary indication for ONS-5010/LYTENAVA.)

Biologics License Application (BLA)

The application submitted to the FDA for approval to market a biologic product. (The regulatory pathway OTLK is pursuing for ONS-5010/LYTENAVA in the United States.)

Complete Response Letter (CRL)

A letter issued by the FDA indicating that an application cannot be approved in its current form, outlining deficiencies. (Indicates the FDA's current rejection of OTLK's BLA, requiring further action.)

Off-label use

Prescribing a drug for a condition or in a manner not officially approved by regulatory authorities. (A significant portion of the current anti-VEGF market relies on off-label bevacizumab, which ONS-5010/LYTENAVA aims to replace with an approved product.)

PDUFA Goal Date

The date by which the FDA commits to review and act on a resubmitted BLA or NDA. (Sets a target for potential FDA approval of ONS-5010/LYTENAVA in the US.)

Year-Over-Year Comparison

This filing indicates a significant shift in Outlook Therapeutics' regulatory status. While the company has achieved marketing authorization and launched ONS-5010/LYTENAVA in Europe, the repeated Complete Response Letters from the FDA for the US market represent a major setback. The company's financial situation continues to be precarious, with substantial doubt about its going concern, underscoring the critical need for successful US FDA approval and continued funding.

Key Financial Figures

• $0.01 — 4,399 shares of common stock, par value $0.01 per share. DOCUMENTS INCORPORATED BY R
• $1.00 — rk on September 30, 2025, or CHF 0.80 = $1.00. We do not represent that CHF were, cou
• $3.6 b — na market estimated to be approximately $3.6 billion, including approximately 1.52 mil
• $8.5 billion — in the United States, with an estimated $8.5 billion total anti-VEGF retina market, where 55
• $16 billion — or anti-VEGF retina to be approximately $16 billion (Citeline (2023), Global Data (2023) an

Filing Documents

• otlk-20250930x10k.htm (10-K) — 2410KB
• otlk-20250930xex4d1.htm (EX-4.1) — 44KB
• otlk-20250930xex10d12.htm (EX-10.12) — 39KB
• otlk-20250930xex21d1.htm (EX-21.1) — 7KB
• otlk-20250930xex23d1.htm (EX-23.1) — 3KB
• otlk-20250930xex31d1.htm (EX-31.1) — 13KB
• otlk-20250930xex31d2.htm (EX-31.2) — 13KB
• otlk-20250930xex32d1.htm (EX-32.1) — 13KB
• 0001104659-25-123264.txt ( ) — 9493KB
• otlk-20250930.xsd (EX-101.SCH) — 57KB
• otlk-20250930_cal.xml (EX-101.CAL) — 68KB
• otlk-20250930_def.xml (EX-101.DEF) — 224KB
• otlk-20250930_lab.xml (EX-101.LAB) — 459KB
• otlk-20250930_pre.xml (EX-101.PRE) — 408KB
• otlk-20250930x10k_htm.xml (XML) — 1521KB

Business

Business 1 ITEM 1A.

Risk Factors

Risk Factors 26 ITEM 1B. Unresolved Staff Comments 83 ITEM 1C. Cybersecurity 83 ITEM 2.

Properties

Properties 84 ITEM 3.

Legal Proceedings

Legal Proceedings 84 ITEM 4. Mine Safety Disclosures 84 PART II 85 ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 85 ITEM 6. Reserved. 85 ITEM 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 86 ITEM 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 103 ITEM 8. Consolidated Financial Statements and Supplementary Data 104 ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 134 ITEM 9A.

Controls and Procedures

Controls and Procedures 134 ITEM 9B. Other Information 135 PART III 136 ITEM 10. Directors, Executive Officers and Corporate Governance 136 ITEM 11.

Executive Compensation

Executive Compensation 136 ITEM 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 137 ITEM 13. Certain Relationships and Related Transactions, and Director Independence 137 ITEM 14. Principal Accounting Fees and Services 137 PART IV 138 ITEM 15. Exhibits and Financial Statement Schedules 138 ITEM 16. Form 10-K Summary 141 In this report, unless otherwise stated or as the context otherwise requires, references to "Outlook Therapeutics," "Outlook," "the Company," "we," "us," "our" and similar references refer to Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc.) and its consolidated subsidiaries. The Outlook logo, Oncobiologics logo, LYTENAVA and other trademarks or service marks of Outlook Therapeutics, Inc. appearing in this report are the property of Outlook Therapeutics, Inc. This report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders. Currency translations between Swiss Francs, or CHF, and United States dollars provided herein are based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York on September 30, 2025, or CHF 0.80 = $1.00. We do not represent that CHF were, could have been, or could be, converted into United States dollars at such rate or at any other rate. Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. All statements other than statements of historica

Business

Item 1. Business Overview We are a biopharmaceutical company that has developed ONS-5010/LYTENAVA TM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD. In June 2025, we launched directly into the initial markets of Germany and the UK. Additionally, our Biologics License Application, or BLA, is currently under review at the U.S. Food and Drug Administration, or FDA, for the use of ONS-5010/LYTENAVA as a treatment for wet AMD in the United States. If approved by the FDA., our goal is to also launch directly in the United States as the first and only approved ophthalmic bevacizumab for the treatment of wet AMD. In addition to Europe and the United States., we may seek approval to launch ONS-5010/LYTENAVA the product in other markets. ONS-5010/LYTENAVA is manufactured in the United States. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody, or mAb, that inhibits VEGF and associated angiogenic activity. Prior to the approval of ONS-5010/LYTENAVA in the EU and UK, bevacizumab had only been approved for use in the treatment of various forms of cancer and had not been optimized for use in the treatment of retina diseases. Because there previously were no approved bevacizumab products for the treatment of retinal diseases in the United States and other major markets, we submitted standard biologic therapeutic applications and are not using the biosimilar drug regulatory pathway that would be required if bevacizumab were an approved drug for the targeted disease. Off-label repackaged bevacizumab is a frequently used first-line anti-VEGF treatment in Europe (approximately 2.8 million injections annually) and the United States (approximately 2.7 million inj

View Full Filing

View this 10-K filing on SEC EDGAR